GlassScriptPhysician profile
Brendan Carolan
NPI 1407015449
$10,513.64
in general payments reported to CMS, 2019-2025
41 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,426 · 2020: $1,062 · 2021: $1,202 · 2022: $1,480 · 2023: $1,922 · 2024: $1,502 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,343.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,253.90 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $2,039.62 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $738.63 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $715.01 | 2019-2025 | Ofev, Spiriva Respimat, Jascayd |
| Novartis Pharmaceuticals Corporation | $662.66 | 2019-2024 | |
| Pfizer INC. | $365.34 | 2019-2025 | |
| Mylan Specialty L.P. | $345.73 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $341.24 | 2021-2025 | Glassia, Cuvitru |
| Amgen INC. | $283.30 | 2022-2025 | Tezspire, Tavneos |
| Grifols USA, LLC | $242.19 | 2021-2025 | Prolastin-C Liquid |
| Abbvie INC. | $229.62 | 2022-2025 | |
| Genentech USA, INC. | $205.24 | 2019-2025 | Xolair |
| Covis Pharma Gmbh | $186.54 | 2021-2023 | |
| United Therapeutics Corporation | $177.20 | 2023-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $171.71 | 2022-2025 | Acthar |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $168.87 | 2019-2025 | Opsumit |
| Merck Sharp & Dohme LLC | $149.78 | 2021-2025 | Zerbaxa, Winrevair |
| Philips North America LLC | $148.79 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Allergan, INC. | $125.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $109.18 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $100.44 | 2021-2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $99.24 | 2019-2020 | |
| Insmed, INC. | $86.49 | 2019-2025 | Arikayce |
| Alexion Pharmaceuticals, INC. | $79.92 | 2019-2021 | |
| Inogen, INC. | $57.23 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $49.15 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $41.95 | 2020-2024 | Eliquis |
| Electromed, INC. | $39.92 | 2019-2024 | Smartvest |
| Shire North American Group INC | $32.76 | 2019 | |
| Paratek Pharmaceuticals, INC. | $31.48 | 2022 | |
| Sanofi Pasteur INC. | $30.93 | 2023 | |
| Baxter Healthcare | $28.93 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inspire Medical Systems, INC. | $28.17 | 2023 | Inspire |
| Astellas Pharma US INC | $24.65 | 2019 | |
| Csl Behring | $24.46 | 2020 | |
| Liquidia Technologies, INC. | $21.45 | 2025 | Yutrepia |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2019 | |
| Circassia INC. | $16.25 | 2019 | |
| Pulmonx Corporation | $16.23 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Advanced Respiratory, INC | $13.94 | 2021 | |
| Bio Products Laboratory USA, INC. | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brendan Carolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.